^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

76-gene signature

7ms
Targeting PDGFRb for superior bladder cancer treatment (SITC 2023)
Moreover, in our BC patients’ cohort and cell lines, we found a downregulation of miR-138–5p expression along with tumor progression, suggesting a negative regulation of the PDGFb/PDGFRb by miR138–5p. Conclusions Our preliminary results reveal the role of PDGFb/PDGFRb in maintaining tumor cells fitness and highlight a molecular loop involving PDGFRb and miR-138–5p in BC, that might represent not only a useful biomarker for improved diagnosis and patients’ stratification, but also as a promising axis that can be therapeutically targeted in situ.
IO biomarker
|
PDGFRB (Platelet Derived Growth Factor Receptor Beta) • PDGFB (Platelet Derived Growth Factor Subunit B) • MIR138 (MicroRNA 138)
|
76-gene signature
almost2years
YAP1 activation is associated with the progression and response to immunotherapy of non-muscle invasive bladder cancer. (PubMed, EBioMedicine)
This study suggests that YAP1 activation has an important prognostic effect on bladder cancer progression and might be useful in the selection of immunotherapy.
Journal • IO biomarker
|
YAP1 (Yes associated protein 1)
|
76-gene signature